Evidence map›Paper›PMID 30818224›Full record

ArticleiScience2019

HDAC2 Regulates Site-Specific Acetylation of MDM2 and Its Ubiquitination Signaling in Tumor Suppression.

Nikita Patel, Juehong Wang, Kumiko Shiozawa, Kevin B Jones, Yanfeng Zhang, Jeremy W Prokop, George G Davenport, Naoe T Nihira, Zhenyue Hao, Derek Wong and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. The role of acetylation and deacetylation in cancer metabolism.Clinical and translational medicine · 2025
    Review
  3. Combination of HDAC and FYN inhibitors in synovial sarcoma treatment.Frontiers in cell and developmental biology · 2024
    Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 8 institutions in 3 countries.

Nikita PatelHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.
Juehong WangHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.
Kumiko ShiozawaDivision of Rare Cancer Research, National Cancer Center, Tokyo 104-0045, Japan.
Kevin B JonesDepartment of Orthopaedics and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
Yanfeng ZhangHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.
Jeremy W ProkopHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA; Department of Pediatrics and Human Development, Michigan State University, Grand Rapids, MI 49503, USA.
George G DavenportHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.
Naoe T NihiraBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
Zhenyue HaoPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2C1, Canada.
Derek WongBiomdical Research Centre, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Laurel BrandsmeierHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.
Sarah K MeadowsHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.
Arthur V SampaioBiomdical Research Centre, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Ryan Vander WerffBiomdical Research Centre, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Makoto EndoGenetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, Vancouver, BC V5Z 1M9, Canada.
Mario R CapecchiDepartment of Human Genetics, University of Utah, Salt Lake City, UT 84112, USA.
Kelly M McNagnyBiomdical Research Centre, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Tak W MakPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2C1, Canada.
Torsten O NielsenGenetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, Vancouver, BC V5Z 1M9, Canada.
T Michael UnderhillBiomdical Research Centre, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Richard M MyersHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.
Tadashi KondoDivision of Rare Cancer Research, National Cancer Center, Tokyo 104-0045, Japan.
Le SuHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA. Electronic address: lsu@hudsonalpha.org.
HudsonAlpha Institute for Biotechnology · USUniversity of British Columbia · CANational Cancer Centre Japan · JPPrincess Margaret Cancer Centre · CAUniversity of Utah · USVancouver Coastal Health Research Institute · CAHarvard University · USMichigan State University · US

Funding

Transposon-insertional Mutagenesis to Decipher OsteosarcomagenesisK08CA138764 · NCI · UNIVERSITY OF UTAH · PI JONES, KEVIN BRUCE · 2009 to 2013
$896k
Using a Sequence-to-Structure-to-Function Approach to Functionally Characterize Protein Coding Missense Mutations in the Human and Rat GenomesK01ES025435 · NIEHS · MICHIGAN STATE UNIVERSITY · PI PROKOP, JEREMY WILLIAM · 2014 to 2018
$489k
NCI NIH HHS K08 CA138764NIEHS NIH HHS K01 ES025435
6 · The paper itself

Abstract

Histone deacetylases (HDACs) are promising targets for cancer therapy, although their individual actions remain incompletely understood. Here, we identify a role for HDAC2 in the regulation of MDM2 acetylation at previously uncharacterized lysines. Upon inactivation of HDAC2, this acetylation creates a structural signal in the lysine-rich domain of MDM2 to prevent the recognition and degradation of its downstream substrate, MCL-1 ubiquitin ligase E3 (MULE). This mechanism further reveals a therapeutic connection between the MULE ubiquitin ligase function and tumor suppression. Specifically, we show that HDAC inhibitor treatment promotes the accumulation of MULE, which diminishes the t(X; 18) translocation-associated synovial sarcomagenesis by directly targeting the fusion product SS18-SSX for degradation. These results uncover a new HDAC2-dependent pathway that integrates reversible acetylation signaling to the anticancer ubiquitin response.

Indexed as

Biological SciencesCancerMolecular Biology

Identifiers

PMID30818224
PMCPMC6393697
OpenAlexW2912634091

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.